Chlordiazepoxide HCl/Clidinium Bromide combines in a single capsule formulation the antianxiety action of chlordiazepoxide hydrochloride and the anticholinergic/spasmolytic effects of clidinium bromide, both exclusive developments of Roche research. Each Chlordiazepoxide HCl/Clidinium Bromide capsule contains 5 mg chlordiazepoxide hydrochloride and 2.5 mg clidinium bromide.
Based on a review of this drug by the National Academy of Sciences National Research Council and/or other information, FDA has classified the indications as follows:
"Possibly" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.
Final classification of the less-than-effective indications requires further investigation.
Clinical Trials Related to Chlordiazepoxide and Clidinium (Chlordiazepoxide / Clidinium)
Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder [Recruiting]
The purpose of this study is to determine whether Pioglitazone as an adjunct to Citalopram
is effective in treatment of moderate to severe depression
A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study [Recruiting]
Non-cardiac chest pain is a common clinical problem encountered in our practice but at
present, the results of treatments are unsatisfactory. The pathogenesis remains unknown but
altered motility of the esophagus and psychological factors including anxiety have been
implicated as important factors. Reports of the single use of anticholinergic drugs and
anxiolytics have yielded conflicting results, has been demonstrated to yield marginal or of
no value. However the use of the combination therapy, especially with a double blind fashion
have not been reported. On that basis, we propose to use a combination of anti-cholinergic
and tranquilliser for the symptomatic treatment of non-cardiac chest pain. The aim of this
study is to evaluate the efficacy of combination therapy of anti-cholinergic and anxiolytic
drugs in the treatment of non-cardiac chest pain.
Alcohol Detoxification in Primary Care Treatment (ADEPT) [Recruiting]
Once someone becomes dependent on alcohol (alcoholic), the risks of complications from
alcohol withdrawal when they stop drinking grow. These can include a life−threatening fit or
delirium tremens (see things, become frightened). To prevent such complications, people take
medication such as benzodiazepines (e. g., valium or librium) in reducing doses for about a
week; this is called detoxification or 'detox.' In the UK effective alcohol treatment exists
but little is known about what is the best detox medication. Alternative drugs to
benzodiazepines appear to protect the brain from the toxicity of alcohol withdrawal and to
reduce the likelihood of drinking again. This study will examine the feasibility of
comparing medication regimens for alcohol detox for the first time in primary care. It will
include a standard detox regimen (librium over 8 days) alone and together with a drug,
acamprosate, that has been shown to reduce toxicity of alcohol withdrawal in preclinical
models and is used after detox to help people remain sober. It will focus on the
practicalities of doing such a study as well as assessing how people feel (withdrawal
symptoms) and do (drinking during first month).
Page last updated: 2009-09-23